Syngeneic mouse model of YES-driven metastatic and proliferative hepatocellular carcinoma
Disease Models & Mechanisms · 2024
DOI: 10.1242/dmm.050553 ↗Kurz gefasst
Fachartikel in der Zeitschrift Disease Models & Mechanisms, 2024. Verfasst von Laure Voisin und 6 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Research in Immunology and Cancer, Montreal, Quebec H3T 1J4, Canada. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Cell Proliferation, Liver Neoplasms, Disease Models, Animal. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Canadian Cancer Society Research Institute, Cancer Research Society, Canadian Liver Foundation.
Abstract (Originalsprache)
Hepatocellular carcinoma (HCC) is a disease of high unmet medical need that has become a global health problem. The development of targeted therapies for HCC has been hindered by the incomplete understanding of HCC pathogenesis and the limited number of relevant preclinical animal models. We recently unveiled a previously uncharacterized YES kinase (encoded by YES1)-dependent oncogenic signaling pathway in HCC. To model this subset of HCC, we established a series of syngeneic cell lines from liver tumors of transgenic mice expressing activated human YES. The resulting cell lines (referred to as HepYF) were enriched for expression of stem cell and progenitor markers, proliferated rapidly, and were characterized by high SRC family kinase (SFK) activity and activated mitogenic signaling pathways. Transcriptomic analysis indicated that HepYF cells are representative of the most aggressive proliferation class G3 subgroup of HCC. HepYF cells formed rapidly growing metastatic tumors upon orthotopic implantation into syngeneic hosts. Treatment with sorafenib or the SFK inhibitor dasatinib markedly inhibited the growth of HepYF tumors. The new HepYF HCC cell lines provide relevant preclinical models to study the pathogenesis of HCC and test novel small-molecule inhibitor and immunotherapy approaches.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute for Research in Immunology and Cancer, Montreal, Quebec H3T 1J4, Canada.
- Centre de recherche du Centre hospitalier de l'Université de Montréal (CRCHUM), Montreal, Quebec H2X 0A9, Canada.
- Department of Pathology and Cell Biology, Université de Montréal, Montreal, Quebec H3C 3J7, Canada.
- Molecular Biology Program, Faculty of Medicine, Université de Montréal, Montreal, Quebec H3C 3J7, Canada.
- Department of Pharmacology and Physiology, Université de Montréal, Montreal, Quebec H3C 3J7, Canada.
ORCID-Profile: Sylvain Meloche
Förderung
- Canadian Cancer Society Research Institute
- Cancer Research Society
- Canadian Liver Foundation
Zitieren
APA
Voisin, L., Lapouge, M., Saba-El-Leil, M. K., Gombos, M., Javary, J., Trinh, V. Q., & Meloche, S. (2024). Syngeneic mouse model of YES-driven metastatic and proliferative hepatocellular carcinoma. Disease Models & Mechanisms. https://doi.org/10.1242/dmm.050553
Vancouver
Voisin L, Lapouge M, Saba-El-Leil MK, Gombos M, Javary J, Trinh VQ, et al. Syngeneic mouse model of YES-driven metastatic and proliferative hepatocellular carcinoma. Disease Models & Mechanisms. 2024. doi:10.1242/dmm.050553
BibTeX
@article{Voisin2024,
author = {Voisin, Laure and Lapouge, Marjorie and Saba-El-Leil, Marc K and Gombos, Melania and Javary, Joaquim and Trinh, Vincent Q and Meloche, Sylvain},
title = {Syngeneic mouse model of YES-driven metastatic and proliferative hepatocellular carcinoma},
journal = {Disease Models & Mechanisms},
year = {2024},
doi = {10.1242/dmm.050553}
}
EUVIMED